EDWARDS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Edwards Lifesciences Corp for allegedly misleading investors regarding the expected revenue growth of its Transcatheter Aortic Valve Replacement (TAVR) platform during the fiscal year 2024 [1][3]. Company Performance - Edwards Lifesciences provided optimistic projections about its TAVR platform, emphasizing strong demand and growth potential in under-penetrated markets [3]. - On July 24, 2024, the company reported disappointing financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the entire fiscal year [4]. - The company attributed the decline in TAVR performance to increased competition from its own new therapies, which strained hospital resources [4]. Market Reaction - Following the announcement of the poor financial results and revised guidance, Edwards' stock price plummeted from $86.95 to $59.70 per share, marking a decline of approximately 31.34% in just one day [5].